Targeting Adhesion G Protein-Coupled Receptor GPR56 in Alzheimer’s Disease
About the Research Project
Program
Award Type
Postdoctoral Fellowship
Award Amount
$200,000
Active Dates
July 01, 2021 - June 30, 2023
Grant ID
A2021020F
Mentor(s)
Xianhua Piao, MD, PhD, University of California, San Francisco
Goals
The proposed project aims to investigate how microglial GPR56 affects the progression of Alzheimer’s disease by using novel mouse models and cutting-edge single-cell transcriptomic approaches.
Summary
The proposed project hypothesizes that microglial GPR56 maintains normal brain homeostasis and prevents the progression of AD pathology. I will test the hypothesis by carrying out: Aim 1 is to explore the function of microglial GPR56 in AD. I will conduct histology and protein analysis and behavior tests on the novel mouse model created by crossing the AD mouse model with microglial GPR56 conditioned knockout mice. Aim 2 is to define the transcriptomic signature of neurons, microglia, and other glial cells in the novel mouse model by single-nucleus RNA-Seq and spatial transcriptomics.
Unique and Innovative
This proposed study provides a novel therapeutic target for Alzheimer’s disease by investigating the role of the adhesion GPCR in microglia. As the second-largest family of GPCRs, adhesion GPCR regulates various developmental and disease processes, but its function in neurodegeneration remains largely unknown. This project highlights the glia-glia communication and neuroinflammation mediated by adhesion GPCR, revealing a potential brand-new signaling pathway and expanding the novel drug development in Alzheimer’s disease.
Foreseeable Benefits
This proposed study investigates how microglial GPR56 regulates microglia-astrocyte communication and neuroinflammation in Alzheimer’s disease mouse model. The success of this study will further extend our understanding of the glial cells’ functions in the disease progression on both molecular and behavioral aspects. These approaches combined will reveal the glial response on amyloid plaques and the signaling pathways mediated by microglial GPR56, advancing both the field of adhesion GPCR and providing novel therapeutic strategies for Alzheimer’s disease.
Related Grants
Alzheimer's Disease Research
Exploring How Signals from the Body Influence Alzheimer’s Disease
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Haoyue Zhou, PhD
Current Organization
Gladstone Institutes
Exploring How Signals from the Body Influence Alzheimer’s Disease
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Haoyue Zhou, PhD
Current Organization
Gladstone Institutes
Alzheimer's Disease Research
Targeting Proinflammatory Molecules Using a Chimeric Receptor to Reduce Inflammation and Tauopathy
Active Dates
July 01, 2026 - June 30, 2029
Principal Investigator
Gilbert Gallardo, PhD
Current Organization
Washington University in St. Louis
Targeting Proinflammatory Molecules Using a Chimeric Receptor to Reduce Inflammation and Tauopathy
Active Dates
July 01, 2026 - June 30, 2029
Principal Investigator
Gilbert Gallardo, PhD
Current Organization
Washington University in St. Louis
Alzheimer's Disease Research
Does Fructose Contribute to Neurodegeneration and Alzheimer's Disease Development?
Active Dates
July 01, 2026 - June 30, 2029
Principal Investigator
Justin Perry, PhD
Current Organization
Memorial Sloan Kettering Cancer Center
Does Fructose Contribute to Neurodegeneration and Alzheimer's Disease Development?
Active Dates
July 01, 2026 - June 30, 2029
Principal Investigator
Justin Perry, PhD
Current Organization
Memorial Sloan Kettering Cancer Center